In This Issue:

Letter from the President 03
Preview of the 2022 Annual Meeting 05
Program Chair Update on 2022 Meeting 13
2022 Awards for Excellence 15
In Memoriam 15
Drug and Alcohol Dependence Journal Corner 16
CPDD’s Committee Reports 17
CPDD EXECUTIVE COMMITTEE

President
William Stoops, Ph.D.

President-Elect
Amy C. Janes, Ph.D.

Treasurer
Jack Bergman, Ph.D.

Past-President
Stacey Sigmon, Ph.D.

Public Policy Officer
Sandra Comer, Ph.D.

CPDD BOARD OF DIRECTORS
Sudie Back, Ph.D.
Qiana Brown, Ph.D., M.P.H., M.S.W., LCSW
F. Ivy Carroll, Ph.D.
Ziva Cooper, Ph.D.
Kelly Dunn, Ph.D., M.B.A.
Albert Garcia-Romeu, Ph.D., M.A.
Deborah Hasin, Ph.D.
Angela Heads, Ph.D.
Jermaine Jones, Ph.D.
Frances Levin, M.D.
Wendy Lynch, Ph.D.
Marco Pravetoni, Ph.D.
James Rowlett, Ph.D.
Dace Svikis, Ph.D.
Michael Taffe, Ph.D.
Erin Winstanley, Ph.D.

CPDD EX OFFICIO

Rules Chair
Charles Gorodetzky, M.D., Ph.D.

Sr. Project Leader
Jesse Howard

EDITOR
Maria Parker, M.P.H., M.S., Ph.D.

CPDD COMMUNICATIONS COMMITTEE
Bethea A. Kleykamp, Ph.D., Chair
Liz Evans, Ph.D.
Lindsey R. Hammerslag, Ph.D.
Jillian E. Hardee, Ph.D.
Lynn Kirby, Ph.D.
Barrett Wallace Montgomery, B.S.
Jacques D. Nguyen, Ph.D.
Joseph J. Palamar, Ph.D.
Maria A. Parker, M.P.H., M.S., Ph.D.
Tasha Perdue, Ph.D.
Irene Pericot-Valverde, Ph.D.
Jonathan J.K. Stoltman, Ph.D.

Want to contribute or advertise in Newsline? Email info@cpdd.org.
Dear friends and colleagues,

As I write this letter to you, I am very excited to see each of you at this year’s annual meeting. I know the past two years have been very hard, with seemingly endless zoom meetings and online only conferences. This year’s meeting will bring an important change for CPDD as it is our first conference that will have both in-person and digital components. We are hoping that the in-person meeting feels much the same as it did before the pandemic, with some important additions for safety (i.e., all attendees must provide proof of vaccination; masks are welcome and STRONGLY encouraged). CPDD digital will feature approximately 70% of the in-person content, including live streamed and recorded sessions, as well as all posters from the in-person meeting. I think these changes bode well for future CPDD meetings being more inclusive for all of our attendees from across the globe.

This year marks our 84th CPDD Annual Scientific Meeting and we celebrated our 93rd birthday. According to research by the American Society of Association Executives, the vast majority of professional societies and associations never see their 10th anniversary. I’d like to express my deepest gratitude to all of our CPDD committee members, the Board of Directors, the Executive Committee and our Parthenon Management Group team who have worked tirelessly to make sure our scientific community continues to grow and thrive despite all of the challenges over the past years.

The annual meeting received more than 750 Symposium, Mini-Symposium, Forum, Workshop, and Poster submissions. I would like to thank Dr. Kelly Dunn and the entire Program Committee for their hard work and tenacity in planning this year’s meeting. This year, all attendees (whether in-person or digital only) can look forward to sessions of interest to CPDD’s scientifically diverse membership, including medicinal chemists, preclinical researchers, human laboratory researchers, clinicians, epidemiologists, and clinical researchers. There’s also a special track for early career members! CPDD continues to partner with ISGIDAR to produce their Annual Meeting on Saturday, June 10. NDEWS, RAMS and the InWomen’s conference will also be held in conjunction with CPDD this year. The pandemic has put a slight damper on this year’s meeting as the NIDA International Forum and the NIDA Early Career (formerly Grant Writing) Workshop will take place virtually. We hope they will be able to join us again in-person next year in Denver.

I also want to highlight the keynote speakers for this year’s Presidential Symposium: Dr. J. David Jentsch from Binghamton University and Dr. Katherine Serafine from the University of Texas at El Paso. Both Dr. Jentsch and Serafine are expert preclinical researchers who will provide us with their perspectives on the vital importance of non-human animal research to understanding substance use disorders and improving human health. They will also discuss scientific and policy challenges faced by preclinical researchers. Please plan to join us for this unique opportunity to hear Dr. Jentsch's and Dr. Serafine's perspectives on the issues we grapple with daily in our work. Don't forget, you can still register for the meeting without having to register onsite. To register, click here. You can also contact the Executive Officer with any questions via email at info@cpdd.org or by calling 615.432.0099.

Because we are returning to an in-person meeting, the CPDD Board of Directors chose to offer six of our Award for Excellence this year. Our highly deserving 2022 recipients are:

- Nathan B. Eddy Memorial Award: Stephen T. Higgins, PhD, Vermont Center for Behavior and Health
- Innovator Award: Linda Dwoskin, PhD, University of Kentucky
- CPDD Mentorship Award: Anthony Riley, PhD, The American University
- Joseph Cochin Young Investigator Award: Andrew Huhn, PhD, Johns Hopkins University School of Medicine
- Marian W. Fischman Lectureship Award: Laura Bierut, MD, Washington University School of Medicine
- Martin and Toby Adler Distinguished Service Award: Eric Strain, MD, Johns Hopkins University School of Medicine

Please join us at the opening Plenary Session as we celebrate each of their contributions to substance use disorder research.

CPDD also provide 81 Travel Awards for the 2022 Annual Meeting. Congratulations on to all of our recipients. You can review the entire list here.
I'm very proud to also announce our next President-Elect and newest members of the CPDD Board of Directors, all of whom will assume office at the end of our 2022 Annual Meeting.

President-Elect
· Deborah Hasin, PhD, Columbia University

Board of Directors
· Francesca Filbey, PhD, University of Texas at Dallas
· Cassandra Gipson-Reichardt, PhD, University of Kentucky
· Silvia Martins, MD, Columbia University
· Angela Moreland, PhD, Medical University of South Carolina

Congratulations to each of you and thank you for your service and commitment to the College!

Lastly, please don’t forget to renew your membership! CPDD membership and conference registrations directly fund our numerous programs, awards, and opportunities for early career scientists. To ensure that we continue advancing substance use disorder research, I encourage you to renew your membership.

I look forward to seeing each of you and your science at our June Annual Meeting!

Warmly,

William W. Stoops, Ph.D., CPDD President
Beyond D9-THC: The Blossoming of Minor Cannabinoids
Chair: Jenny Wiley, RTI International
Co-Chair: Inna Belfer, LNG, NIAAA, NIH
Sunday, June 12th from 4:30 PM to 6:00 PM CDT

In addition to its major psychoactive constituent [D9-tetrahydrocannabinol (THC)], the cannabis plant (Cannabis sativa/indica) contains over 100 phytocannabinoids as well as over 500 other identified chemicals, including the terpenoids that give cannabis its distinctive flavoring and aroma. The degree to which these minor plant constituents contribute to the psychoactive and medicinal effects of cannabis is under active investigation. The speakers in this symposium will provide an overview of their work with selected minor cannabinoids, ranging from molecular pharmacology to preclinical studies and clinical trials.

Using Behavioral & Brain Biotypes to Enhance Treatment Outcomes in Addiction Medicine
Chair: Hamed Ekhtiari, University of Minnesota
Co-Chair: Amy Janes, NIDA
Sunday, June 12th from 4:30 PM to 6:00 PM CDT

Patient-tailored therapy promises to improve outcomes for those with a substance use disorder. To address this aim, this symposium focuses on the intersection of brain and behavior to phenotype individuals, with the goal of driving more personalized pharmacological and neuromodulatory treatments.
The Best Offense is Defense! Blocking & Tackling Stimulants in the Periphery to Prevent CNS Action  
Chair: Katrina Foster, NIH, NIDA, DTMC  
Co-Chair: David White, NIH, NIDA  
Monday, June 13th from 10:00 AM to 11:30 AM CDT

An overview of alternative approaches that are currently in pre-clinical and clinical development for treating stimulant use disorders and stimulant overdose by preventing or reducing stimulant activity in the CNS.

Dose-Dependent Subjective Effects of THC & Cannabis Concentrates: From Naturalistic Investigation to Population Analysis  
Chair: Adrianne Wilson-Poe, Legacy Research Institute  
Co-Chair: Ziva Cooper, UCLA Cannabis Research Initiative  
Monday, June 13th from 10:00 AM to 11:30 AM CDT

Despite the increased prevalence and health risks of high-THC cannabis products, their subjective effects and safety are poorly characterized. This session will focus on the subjective effects of high potency cannabis products and cannabis concentrates, with an emphasis on young adults.

From Bench to Bedside to Policy: Updating Our Understanding of Kratom  
Chair: Kirsten Smith, NIDA, NIH IRP  
Co-Chair: Oliver Grundmann, University of Florida  
Monday, June 13th from 10:00 AM to 11:30 AM CDT

Our translational symposium on kratom will feature talks from experts focused on unique aspects of this complex psychoactive plant and its heterogenous population of consumers. These talks will include an overview of real-world kratom use for nonmedical self-treatment of pain, psychiatric, and substance use disorder symptoms as well as use for recreation; a summary of the molecular structure of kratom’s best-studied alkaloids, their pharmacological effects, and the variability of kratom leaves and products; and, lastly, an update on US kratom regulation and policy.

The Importance of Gender, Culture, & Intersectional Issues in Substance Use Interventions: Lessons in Health Disparity Research in South Africa & the U.S.  
Chair: Felicia Browne, RTI International  
Co-Chair: Wendee Wechsburg, RTI International  
Monday, June 13th from 10:00 AM to 11:30 AM CDT

This specific study aims to share the stages of intervention research and the lessons learned from conducting NIH-funded, cross-cultural, and global collaborative research, and present the process/outcome evaluation data from evidence-based substance-use interventions. These interventions contained data from attributes that met the requested criteria: young women, women who are pregnant and couples of African descents. This symposium will allocate time for an interactive discussion about how these projects have offered professional and career development for a diversity of investigators, students, and staff.
Increasing evidence supports a bidirectional relationship between substance use disorders (SUDs) and sleep impairments. Speakers in this mini-symposium will cover topics including mechanisms underlying sleep and how neurobiological changes associated with SUD may contribute to altered sleep, and how persisting sleep impairments may influence relapse potential. Speakers will present data spanning rodent and non-human primate studies covering a range of topics in a field that is of high relevance to both basic and clinical scientists.

Gabapentin is increasingly prescribed off-label in the treatment of opioid use disorder to mitigate physical and mental distress. However, non-medical use and involvement in opioid overdose are on the rise, with resulting labeling changes and state-level changes in scheduling highlighting the increased risks associated with concomitant use of gabapentin with opioids. This mini-symposium utilizes data from a national drug surveillance program to further understand non-medical use, diversion, and adverse events associated with gabapentin in the United States, particularly among those with opioid use disorder.

Extended reality (XR) can be defined as an artificial environment that is experienced through sensory stimuli (such as sights and sounds) provided by a computer and in which one’s actions partially determine what happens in the environment. Speakers will discuss ongoing research efforts related to XR as a medical device, with specific attention to patient-centric study design. Panelists will also discuss existing regulatory hurdles for XR devices and opportunities to ensure that developed solutions are accessible to substance use disorder patients of diverse socio-economic backgrounds, including underrepresented, and vulnerable populations.
In 2020, NIDA funded the second iteration of the National Drug Early Warning System (NDEWS) to address the shifting landscape of drug use in the US, particularly the proliferation of new psychoactive substances (NPS), such as fentanyl and its analogs, synthetic cathinones, and synthetic cannabinoids. Real-time surveillance is needed to detect early signals of new and emerging drug trends and inform prevention efforts, and the new iteration of NDEWS has established multiple data sources to provide an integrated and comprehensive characterization of drug use and availability. This workshop will discuss the NDEWS Scientific Advisory Group, Sentinel Sites, Weekly Briefings, and four methods for surveillance, including:

1. Rapid Street Reporting utilizing on-the-ground rapid surveys of NPS use in Sentinel Site locations and pairing self-report methods with hair sampling.
2. Assessment of real-time substance-related 911 dispatch data.
3. Collaborations with High-Intensity Drug Trafficking Area (HIDTA) programs and RADARS for monitoring of drug seizures and exposures reported to national Poison Control Centers.
4. Real-time web monitoring of Reddit drug-related discussion forums.

Trainees from the University of Florida, NIDA T32 Predoctoral Training Program, and Florida Atlantic University spearheading these NDEWS projects will present their methods and ongoing surveillance findings at this symposium.

Opioid receptor agonists acting primarily at mu opioid receptors are widely prescribed to treat pain. They are effective analgesics, but they carry liabilities that include dependence, tolerance, respiratory depression, nausea, somnolence, constipation, and abuse potential. Moreover, opioid analgesics are less effective for treating certain pain modalities such as inflammatory and neuropathic pain. This symposium will present preclinical and clinical progress on NIDA-supported efforts to develop safe and effective non-opioid analgesics that would potentially reduce exposure to opioids by both new and existing patients with acute and chronic pain conditions.

Major topics focus on reciprocal interactions between drugs of abuse, clock genes involved in circadian rhythms and sleep, and how these interactions impact perineuronal nets and extracellular matrix components in rodents and humans. This session will cover recent findings showing that extracellular matrix components, including perineuronal nets, may serve as key mechanistic links between substance use disorders (SUDs) and disrupted sleep and circadian rhythms. Sleep and circadian rhythms are disrupted in individuals with SUDs.
This symposium will describe what we currently know about the impact of long-term cannabis use and dependence on brain and behavior. Taking a cross-cultural and cross-jurisdictional perspective, we will critically evaluate the role of different user characteristics, discuss important knowledge gaps, and evaluate novel tools to globally harmonize cannabis research.

Innovative approaches are desperately needed to continue the expansion of OUD treatment access. In this session, presenters will share their recent scientific efforts to develop and evaluate novel approaches for expanding the delivery of pharmacotherapy and harm reduction. Presentation topics will include ED-initiated buprenorphine; a 7-day injectable, extended-release buprenorphine formulation; expanding MOUD in criminal justice settings; the role of pharmacists in SUD treatment and harm reduction; technology-assisted buprenorphine treatment for reducing illicit opioid use and overdose risk in rural settings.

Early life adversity (ELA) is a term that is being used to describe traumatic events that occur during childhood which have the potential to alter normal development and increase risks for a spectrum of physical and mental health in adulthood, including substance use disorders (SUDs). Accumulating evidence has shown associations between ELA and risk behaviors, drug misuse, more rapid transition from misuse to use disorders, and poor treatment outcomes in humans. These findings have mirrored those of preclinical studies demonstrating the consequences of early life manipulations on behaviors that reflect aspects of drug reward or tendency to relapse after abstinence.

Nevertheless, ELA is only beginning to be taken into consideration in the development of individualized prevention and treatment strategies and there is a need for a better understanding of the neurobiological processes that promote vulnerability or resilience in ELS-exposed individuals. This symposium will begin with a presentation by Dr. Khan who will discuss the role of ELAs in substance abuse risks, highlighting current findings on mediating pathways that may help to inform intervention strategies. Dr. al'Absi will then review evidence of neurobiological mechanisms that underlie risks for addiction, focusing on the physiological stress system. Dr. Nugent will present her findings showing the effects of ELA on behavior depression and motivational properties of morphine and its relationship to habenula activity in a rat model. Finally, Dr. Hales will discuss the impact of ELA on nociception in mice and their response to morphine and its implications for opioid treatment of chronic pain.
In this one-hour Oral Session, the Editor-in-Chiefs for Drug and Alcohol Dependence (DAD) and Drug and Alcohol Dependence Reports (DADR) will make a brief presentation on their perspectives for the next year.

1. Vital stats of DAD and DADR: submission rate/acceptance rate/impact factor
2. Snapshots of the most important papers published over the last year in DAD and DADR?
3. What puts a submission on track to be the ‘best’ published of the year?
4. What causes a submission to be rejected without review and authors’ next steps?
5. Role of reviewers: What makes a review helpful to authors; what can be learned by being a reviewer?
6. Ensuring diversity and inclusion in peer-reviewed journals

The number of older adults (65 years and over) is expected to more than double over the next 30 years and for the first time ever older adults will make up nearly a quarter of the US population. At the same time, there is evidence that substance use disorders (SUDs) among older adults are increasing including drug-related overdoses. This symposium will include four presentations addressing SUDs (tobacco, cannabis, opioid) and multimorbidity, risk perceptions, and health equity in this underrepresented patient population.

This symposium will present findings on biological, psychosocial, and contextual risk factors for hazardous use and cannabis use disorder across multiple modalities (laboratory paradigms, stress biomarkers, intensive longitudinal designs). This research will review several biopsychosocial risk processes with a focus on modalities of cannabis use, stress and cannabis cue motivation, and sex differences in cannabis users that may underlie patterns of problematic use.
Accumulating evidence demonstrates that the hypocretin/orexin (ORX) neuropeptide system and its constituent CNS receptors play a significant role in the development and maintenance of substance use disorder (SUD). The biobehavioral components through which ORX contributes to SUD are still being elucidated; regulation of motivational, stress/anxiety, sleep, and energy homeostasis systems are strongly implicated. This symposium will provide an update on mechanisms and treatment interventions involving the ORX system in addiction. Presentations will include both preclinical and human studies and feature investigations covering a range of abused substances.

This symposium addresses metacognitive and interoceptive deficits in addiction that can lead to problems in social functioning and contribute to a low treatment success rate and high levels of relapse. We will discuss metacognition and interoception in addiction overall, as well as in the light of emerging treatments with psychedelics and related compounds, inducing so-called non-ordinary states. Such treatments could have the potential to make a long-awaited change in substance use disorders treatments, restoring the social functionality of people suffering from substance use disorders.

Opioid use during pregnancy remains a significant public health concern. The voices of perinatal women with OUD, their families, and healthcare providers must be heard to understand their needs and to address stigmatization and discrimination that undermine health during the vulnerable perinatal period. The studies presented include quantitative and qualitative feedback from these groups related to prenatal initiation of medications for opioid use disorder, navigating healthcare and social systems, and the use of a digital tool for including family in standardizing care for neonatal abstinence syndrome.
The use of technology as part of SUD treatment can promote access to care, personalized medicine, measurement-based care, recovery, and wraparound care.

This symposium will explore novel and innovative utilization of technological tools to serve in addiction healthcare. First, Dr. Polak will present recent findings examining the efficacy of a fully automated contingency management app targeting self-monitoring of pain symptom severity and prescription opioid use in a sample of individuals with chronic pain. Next, Dr. Ingersoll will discuss the application of an mHealth platform deployed by HIV care clinics to increase treatment engagement in substance users vs. non-substance users. Finally, Dr. Ondersma will discuss the development and implementation of a digital platform facilitating tailored SUD interventions.
Hello CPDD members,

This year we are thrilled to be able to welcome you back to in-person programming. We have developed an exciting program for you that we believe truly highlights the breadth and scope of research being conducted by our members.

Expectations for programming have evolved considerably in the past two years as we all adjusted to virtual platforms and programming and this year we have adopted some of those practices for our in-person programming. Our symposia have been changed; we have removed the discussant role and replaced it with a moderated Q&A period. This will provide our attendees with the unique in-person opportunity to hear the panel of speakers discuss questions amongst themselves and learn from each other. You will be able to submit your questions in real-time from the audience. Among our extensive array of wonderful sessions, we have 4 solicited symposia that focus on early life trauma, minor cannabinoids, the orexin system, and artificial intelligence/virtual reality. This year we’ve also solicited a workshop related to medical device development, an exciting growth area in our field.

This year also marks the launch of a new feature, a Small Business Poster Session. We worked with the NIDA OTIPI office to encourage poster submissions from SBIR recipients and we have programmed this as part of a small business track. We encourage all attendees to attend this session and talk with these innovators, there are great opportunities to form research collaborations and bolster the impact of your own projects by integrating these new technologies into your research.

One trend that has emerged over the past two years is a preference for shorter programming blocks. We embraced this by shifting all oral communications to 1-hour sessions this year. That strategy allowed us to program a much wider array of topics than in prior years and to more easily profile some emerging areas of research for which only a few experts exist. Examples include sessions on monoclonal antibodies or the effects of neighborhoods on drug use behaviors. We also took extreme care to balance programming to ensure a preclinical session was scheduled at every timepoint, and we worked hard to promote early career presenters and to diversify the speaker panels with regard to gender, race, and ethnicity. We will continue our work in this area moving forward.

This year we are also building off the value of mixed virtual and in-person programming to design a virtual program that we believe is complementary to our in-person program. This will be of significant value to our colleagues who are unable to attend, and we paid particular attention to include programming that may have appeal to international and student members. We will ask all posters to include a virtual upload, all oral communications to provide a short virtual talk, and have identified two sessions per time slot that will be taped in real-time for transition to the virtual platform. Those real-time programs will also host a Q&A after the meeting so our virtual-only attendees can ask questions. The best part is that virtual programming will be available to all in-person attendees as well, so we can all continue to watch programming from our colleagues.

Finally, despite these new additions to our programming, many of our beloved aspects remain. We will have our plenary and presidential sessions, presentation of awards (including the 2020 and 2022 Eddy and Fischman awardees), two late-breaking sessions, a Drug and Alcohol Dependence session, an impressive line-up of symposia and workshops that were developed by our members, an early career session, a pre/postdoctoral mixer, our standard forums, several scientific research posters, Brunch with Champions, and more. This is my final year as the Chair of this impressive and talented committee and I am confident it will be the most exciting year yet. Can’t wait to see you in Minneapolis!
84th ANNUAL SCIENTIFIC MEETING
Minneapolis, MN • June 11-15, 2022

Get ready! #CPDD22 returns as an in person meeting.

REGISTER NOW
The CPDD Awards for Excellence Committee is quite literally the most rewarding committee of the College! Our committee is privileged to administer the Nathan B. Eddy Memorial Award, the Marian W. Fischman Lectureship Award for An Outstanding Woman Scientist, the Mentorship Award, the Joseph Cochin Young Investigator Award, the J. Michael Morrison Award, and the Innovator Award. We are pleased to announce the following winners of the 2022 CPDD Awards for Excellence (Note that the J. Michael Morrison Award was not offered this year). Congratulations, award winners!

**Nathan B. Eddy Memorial Award:** Stephen Higgins, Ph.D., University of Vermont  
**Marian W. Fischman Lectureship Award:** Laura Bierut, M.D., Washington University School of Medicine  
**Mentorship Award:** Anthony Riley, Ph.D., American University  
**Joseph Cochin Young Investigator Award:** Andrew Huhn, M.B.A., Ph.D., Johns Hopkins University School of Medicine  
**Innovator Award:** Linda Dwoskin, Ph.D., University of Kentucky

Please join us in congratulating our colleagues for their outstanding achievements!

We also want to take this opportunity to remind everyone of a couple of nomination rules (please see our SOP for full details). First, individuals can only nominate one person for an award but are permitted to submit nominations for more than one award, with the restriction that the same person cannot be nominated for more than one award in the same year. Second, Awards for Excellence Committee members are not allowed to be nominated for an award. Thank you for keeping these restrictions in mind when considering potential award nominees.

Our committee would also like to remind the membership that we are committed to a confidential, yet transparent, review process. The committee members represent the diversity of interests of the College and are required to disclose actual or perceived conflicts of interest with any of the nominees—those with conflicts do not participate in the review process for a given award. The review process is like an NIH Study Section: committee members are provided the confidential materials for each nominee, they review the materials and provide preliminary scores, and those preliminary scores are used to guide the review discussion. Merit is the primary criterion, but diversity is encouraged and embraced.

Lastly, we want to address an issue that has come up a few times with the committee over the years. Specifically, we have been approached about the possibility of nominating a deceased CPDD member for the Awards for Excellence. Although we are highly supportive of honoring past CPDD members, there are concerns about the potential bias it could generate during the selection process. CPDD leadership has suggested that the mini-symposium mechanism could be used to honor past members and indicated that those submissions would receive priority (as long as the submission meets the standard requirements). Please consider this option in the future if you would like to honor a deceased scientist from our field.

I am honored to continue to serve as the Chair for the Awards for Excellence Committee and look forward to working with the Committee and the College to recognize the best and brightest of our members in the coming years. Please consider nominating deserving colleagues for one or more of the CPDD Awards for Excellence next year.

---

**In Memoriam**

CPDD celebrated the lives and accomplishments of our distinguished members. Please join us in celebrating the lives of those we lost since our last issue.

Alan Gintzler, PhD  
Martin Iguchi, PhD  
Mary Jeanne Kreek, MD  
Roy Pickens, PhD  
Richard Saitz, MD

Read their memorials by clicking [here](#).
Lifetime Marijuana Use and Epigenetic Age Acceleration: A 17-Year Prospective Examination

This prospective longitudinal study followed a community sample of 154 participants annually from age 13 to age 30 to assess links between lifetime levels of marijuana use and accelerated epigenetic aging. Lifetime use predicted accelerated epigenetic aging with effects remaining even after covarying cell counts, demographic factors, cigarette smoking, and chronological age. A dose-response effect was observed and there was also evidence that effects were dependent upon recency of use. Effects of marijuana use appeared to be fully mediated by hypomethylation of a site linked to effects of hydrocarbon inhalation, suggesting that effects may be primarily due to hydrocarbon inhalation among marijuana smokers.

Epigenome-Wide Association Analyses of Active Injection Drug Use
Chang Shu, Andrew E. Jaffe, Sarven Sabunciyan, Hongkai Ji, Jacquie Astemborski, Jing Sun, Kelly M. Bakulski, David Sosnowski, Shruti H. Mehta, Gregory D. Kirk, Brion S. Maher

Using blood collected from the same subjects at multiple timepoints, we identified several sites in the genome that were differentially methylated during periods of active injection drug use versus abstinence. These sites are in biological pathways involved in immune response, insulin regulation and epinephrine synthesis. There was also a half-year acceleration in methylation-estimated biological age when comparing samples collected during periods of active injection vs. abstinence within the same subject. Findings demonstrate that these changes can be seen over a relatively short period. Results also provide insight into epigenetic changes during periods of drug use versus abstinence.
The Communications Committee is moving forward with several initiatives to increase member and public awareness of substance use research. Efforts include continuing existing committee work, including supporting the production of Newsline by Editor Dr. Maria Parker and reviewing submissions to the News and Views section of Drug and Alcohol Dependence. News and Views submissions are welcomed from all members to highlight new advances in substance use research and promote activities of CPDD. The committee has recently updated the instructions for News and Views submissions, including a limit of 2,500 words and the requirement that all submissions be reviewed by two committee members and by the CPDD Executive Committee. In addition, Dr. Barrett Montgomery has recently been designated as the News and Views Editor. The committee will be sharing a detailed overview of these changes in the coming months, including a call for specific submission topics. Stay tuned!

In addition, the committee is taking on new efforts to increase social media engagement and science communication at CPDD. These efforts include the designation of a social media outreach lead, Dr. Jillian Hardee and Dr. Barrett Montgomery. Weekly updates are posted to CPDD’s Twitter feed highlighting substance use research. In addition, with the assistance of committee member Dr. Jonathan Stoltman, an updated Media Forum was developed and accepted as a workshop that will take place at the annual conference in June. The new Forum model is focused on helping attendees learn best practices in science journalism, including pitching stories to editors and posting research on social media such as Twitter.

The committee is also planning new initiatives for 2022 to address special populations in substance research and stigma. Some options that have been proposed include designing a webinar or other type of presentation that can be shared with the CPDD community. Topics might include expert-guided overviews of newly released guidance in substance use research, an overview of best practices in science writing and communication, and a detailed discussion of the impact of stigma on substance use research and treatment. The committee will plan these efforts during bi-monthly meetings throughout 2022. If members are interested in proposing potential topics for webinars or News and Views submissions, please reach out to Dr. Annie Kleykamp (akleykamp@gmail.com).

The committee will present its annual forum in the CPDD 2022 meeting. The title is ‘Resuming Research on Substance Use Disorders after Lifting COVID-19 Distancing Measures: Challenges and Opportunities’. The chairs for the forum will be Omayma Alshaarawy and Elizabeth Santa Ana, and the speakers include Elizabeth Santa Ana, Ursula Myers, Steven Ondersma and Maureen Reynolds.

We are working on creating an online platform for CPDD researchers to seek and discuss issues related to conducting drug use research in humans. This platform will be available to researchers all year around and will complement the annual meeting forum/workshop efforts.
The International Committee (IC) is dedicated to promoting substance abuse research and treatment at the international level by recognizing promising scientists, assisting the NIDA International Program, and assisting CPDD members in other countries in the scientific study of drug dependence.

To that end, the IC submitted a request and received approval from the CPDD Board of Directors to lower the costs for researchers from low-to-middle income countries (as designated by The World Bank). The discounted fees will be approved and implemented after the next BOD meeting.

The IC will also host its second workshop following the success of the inaugural workshop at last year’s virtual meeting. The ‘in real life workshop’ is entitled, “Did You Hear About the Looming Global Fentanyl Crisis?: A Quick Start for Addiction Scientists Across the World” with presentations from Paul Griffiths, Kevin Mulvey, Thom Browne, and Steve Gust on current data and resources for an international audience to address potential worldwide fentanyl crisis.

The IC also selected recipients of the CPDD International Travel Awards, which included Dr. Suzaily Wahab (University Kebangsaan Malaysia Medical Centre, Malaysia), Dr. Gayatri Bhatia (All India Institute of Medical Sciences), and Dr. Afolabi Oyapero (Lagos State University College of Medicine). The IC awarded the NIDA Forum Best Poster Award to Dr. Enjeline Hanafi (Faculty of Medicine Universitas Indonesia) for her poster entitled, “Evidence of Telemedicine from a Developing Country During the COVID-19 pandemic: A Virtual Relapse Prevention Program Among a Clinical Sample of Substance-Use Disorder Patients”.

Finally, the IC expresses its gratitude to Dr. Steven Gust who retired as NIDA International Director in 2021. Dr. Gust’s partnership and commitment to the international program have made significant contributions to IC and positive impacts on the international community of substance use researchers.

The purpose of the Long-Range Planning Committee this year is to help guide CPDD into the future by providing oversight of our strategic plan. The new strategic plan was developed by the LRPC with leadership by CPDD 2019-2020 President Dr. Elise Weerts, with input from Parthenon Management Group, multiple committees, the CPDD membership survey and College members. Our committee is now charged with helping to guide and implement its 5 goals. While many changes identified within the new strategic plan are already underway, it is expected that the overall plan will take 3-5 years to implement.

The LRPC has been meeting regularly via conference calls to begin identifying the steps necessary to advance the
The Membership Committee continues to focus on the review of membership applications and pursuing efforts to attract new members to the college. We now review applications on a more frequent basis (6 times per year) and review MIT applications monthly. We also continue to discuss strategies to encourage new members to join the college. As a membership committee, it's important for us to serve as member advocates, but we also rely on the college at large to encourage membership applications from your professional networks and trainees. We are also excited to work more closely with the Unrepresented Populations Committee (URPOP), who joined our January committee meeting to discuss their initiatives.

The CPDD Travel Awards Committee is excited for the return of TRAVELING to the annual meeting. It seems that many junior investigators share that sentiment as we received many applications for the various travel awards affiliated with the conference. We received 90 applications for 30 CPDD Early Career Investigator Travel Awards, 28 applications for 3 FORCE Travel Awards, 32 applications for 20 NIDA Director’s Travel Awards, 31 applications for 20 NIDA Women and Sex/Gender Travel Awards, and 10 applications for 1 Holtzman Travel Award for Preclinical Investigators. Congratulations to all those who received travel awards!

We have a great line-up for the Brunch with Champions this year, so, if you have not already done so, please register for the event by clicking [here](#) and select the "Brunch with Champions in the "Optional Registration Types". The Brunch is a great opportunity for pre-docs, post-docs, and junior faculty to chat informally with senior investigators in the drug abuse research field. Attendance is limited to people who have received their terminal degree within the last 10 years and are at or below the rank of Assistant Professor (or equivalent). The brunch will be held on Wednesday, June 15th, from noon to 1:30 PM CDT, in the conference hotel. Please note that this is the last day of the conference and plan your travel accordingly. I highly encourage pre-registration because attendance will be limited. In the past, the brunch has filled early, and we have had to turn away people who waited too long to register.
The Champions attending the brunch this year include:

- Kathleen Brady, Professor and Vice President for Research at the Medical University of South Carolina
- Alan Budney, past CPDD president; Professor at Dartmouth College
- Silvia Calderon, Controlled Substances Staff; FDA Center for Drug Evaluation and Research
- Kathryn Cunningham, past CPDD president; Professor at University of Texas Medical Branch
- Cassie Gipson-Reichardt, 2021 Cochin winner; Associate Professor at the University of Kentucky
- Jack Henningfield, Vice President of Research, Health Policy and Abuse Liability at Pinney Associates; Adjunct Professor, Johns Hopkins University
- Stephen Kohut, 2019 Cochin winner; Assistant Professor at Harvard Medical School
- Sharon Walsh, past CPDD president; Professor at the University of Kentucky

I would like to thank Chris Cunningham, Colleen Hanlon, Renee Johnson, Aaron Johnson, Therese Kosten, Kevin Munane, Glenn-Milo Santos, Golfo Tzilos Wernette, and Rich Yi for their service on the committee as they rotate off after this year’s meeting. At the same time, we welcome new members Ty Schepis, Kathryn McHugh, Dustin Lee, Shanna Babalonis, Judith Tsui, Tory Spindle, Chuan-Yu Chen, Kirsten Smith, Yatan Pal Singh Balhara, Thiago Fidalgo, and Yukiko Washio who each begin service on the committee in preparation for the 2023 meeting. Lastly, I will also be rotating off the committee this year and am happy to announce that Steve Kohut will be taking over as Chair of the Travel Awards committee. Thanks Steve and best of luck!
MEMBERSHIP

Applications Due
July 31, 2022

REFER A COLLEAGUE